<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04952012</url>
  </required_header>
  <id_info>
    <org_study_id>2020-678</org_study_id>
    <nct_id>NCT04952012</nct_id>
  </id_info>
  <brief_title>The Effect of Thyroid Antibodies on Female Reproductive Function and Pregnancy Outcomes</brief_title>
  <official_title>The Effect of Thyroid Antibodies on Female Reproductive Function and Pregnancy Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First People's Hospital of Yuhang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taizhou Women and Children's Hospital Affiliated to Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changxing People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some women at reproductive age have positive antithyroid antibodies (ATAs). Thyroid&#xD;
      peroxidase antibody (TPOAb) and thyroglobulin antibody (TgAb) are the most common ATAs. This&#xD;
      study aimed to evaluate the impact of ATAs on maturation of women reproductive system and&#xD;
      pregnancy outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of pregnancy complications in women with or without thyroid antibodies</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Thyroiditis, Autoimmune</condition>
  <arm_group>
    <arm_group_label>ATA-positive</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>ATA-negative</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LT4</intervention_name>
    <description>LT4 is used to improve the thyroid function of pregnant women.</description>
    <arm_group_label>ATA-negative</arm_group_label>
    <arm_group_label>ATA-positive</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects were all in the 1st trimester of pregnancy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age during 18-45y;&#xD;
&#xD;
          -  Women tested for TPOAb and/or TgAb, TSH, free T3, free T4, total T3 and total T4&#xD;
             during the 1st trimester of pregnancy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multiple pregnancies;&#xD;
&#xD;
          -  Age &lt; 18 y or &gt; 40 y;&#xD;
&#xD;
          -  L-T4 or PTU intervention before pregnancy;&#xD;
&#xD;
          -  Other autoimmune diseases.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Min Jin</last_name>
    <phone>057187783759</phone>
    <email>min_jin@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Second Affiliated Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Jin</last_name>
      <phone>057187783777</phone>
      <email>min_jin@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 20, 2021</study_first_submitted>
  <study_first_submitted_qc>July 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroiditis</mesh_term>
    <mesh_term>Thyroiditis, Autoimmune</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

